Glycorex Transplantation
1.895
SEK
-2.82 %
GTAB B
NGM Main Regulated
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
-2.82%
+28.91%
+22.26%
+80.48%
+104.2%
+43.02%
+7.67%
-80.74%
-71.8%
-81.34%
glycorex.com
Glycorex Transplantation is a biotechnology company. The company conducts research, development, and marketing within the field of organ transplantation. The main product of the company, Glycosorb-ABO, enables transplants irrespective of the blood type of the donors and the recipients. Transplants with the help of the company's product have been carried out worldwide. Glycorex Transplantation was founded in 1996 and is based in Lund.
Revenue
29.96M
EBIT %
-101.07 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NGM Main Regulated
GTAB B
Daily low / high price
1.8 / 1.92
SEK
Market cap
139.95M SEK
Turnover
73.43K SEK
Volume
40K
Financial calendar
Interim report
2024-11-28
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 10.9 % | 7.8 % |
| Wendt Investment AB | 7.1 % | 5.1 % |
| Glycorex AB | 6.7 % | 17.0 % |
| Nilsson, Kurt med maka och bolag | 3.1 % | 18.5 % |
| Henningson Affärsfastigheter AB | 3.0 % | 2.1 % |
| Nordnet pensionsförsäkring AB | 3.0 % | 2.1 % |
| Wendt Cecilia | 2.0 % | 1.5 % |
| Skandia Försäkrings AB | 1.9 % | 1.9 % |
| Bill Nederman | 1.7 % | 1.2 % |
| Richard Hansson | 1.5 % | 1.1 % |
ShowingAll content types
Glycorex Transplantation AB (GTAB B): In vitro-tester i USA
Glycorex Transplantation AB (GTAB B): Resultat från norsk trombocytutvärdering presenterat vid kongress
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools